S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:HOOK

Hookipa Pharma - HOOK Stock Forecast, Price & News

$1.34
-0.12 (-8.22%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.31
$1.48
50-Day Range
$1.27
$1.73
52-Week Range
$1.23
$6.05
Volume
324,325 shs
Average Volume
161,569 shs
Market Capitalization
$73.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Hookipa Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
497.0% Upside
$8.00 Price Target
Short Interest
Healthy
1.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Hookipa Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.29) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

372nd out of 1,093 stocks

Pharmaceutical Preparations Industry

166th out of 547 stocks

HOOK stock logo

About Hookipa Pharma (NASDAQ:HOOK) Stock

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Stock News Headlines

Aquestive Therapeutics: FDA Stymies Libervant Launch
HOOKIPA Announces Executive Leadership Changes
Recap: HOOKIPA Pharma Q1 Earnings
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Company Calendar

Last Earnings
11/12/2021
Today
10/01/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+497.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-75,660,000.00
Net Margins
-632.09%
Pretax Margin
-632.07%

Debt

Sales & Book Value

Annual Sales
$18.45 million
Book Value
$2.87 per share

Miscellaneous

Free Float
52,189,000
Market Cap
$73.31 million
Optionable
Not Optionable
Beta
0.77

Key Executives

  • Mr. Joern Aldag (Age 60)
    Pres, CEO & Director
  • Mr. Daniel Pinschewer (Age 44)
    Founder & Chief Scientific Officer
  • Dr. Reinhard Kandera (Age 50)
    CFO & Director
  • Mr. Anders Lilja Ph.D. (Age 46)
    Sr. VP of Technical Devel.
  • Mrs. Nina Waibel
    Communications & Investor Relations Mang.













HOOK Stock - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price forecast for 2022?

7 equities research analysts have issued 1 year target prices for Hookipa Pharma's shares. Their HOOK share price forecasts range from $3.00 to $11.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 497.0% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2022?

Hookipa Pharma's stock was trading at $2.33 at the start of the year. Since then, HOOK stock has decreased by 42.5% and is now trading at $1.34.
View the best growth stocks for 2022 here
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.09. The firm had revenue of $3.87 million for the quarter, compared to the consensus estimate of $5.24 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 63.32% and a negative net margin of 632.09%. During the same period in the previous year, the company posted ($0.53) EPS.

What other stocks do shareholders of Hookipa Pharma own?
When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $1.34.

How much money does Hookipa Pharma make?

Hookipa Pharma (NASDAQ:HOOK) has a market capitalization of $73.31 million and generates $18.45 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The official website for the company is www.hookipapharma.com. The company can be reached via phone at 431-890-6360, via email at ir@hookipapharma.com, or via fax at 43-1890-636-0399.

This page (NASDAQ:HOOK) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.